MARKET

GENB

GENB

Generate Biomedicines
NASDAQ
15.71
-0.16
-1.01%
Opening 11:37 07/09 EDT
OPEN
15.85
PREV CLOSE
15.87
HIGH
16.18
LOW
15.59
VOLUME
166.96K
TURNOVER
--
52 WEEK HIGH
18.18
52 WEEK LOW
11.00
MARKET CAP
2.01B
P/E (TTM)
-14.7277
1D
5D
1M
3M
1Y
5Y
1D
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday
NASDAQ · 2d ago
Tesla, AMD, and SpaceX headline Cathie Wood's biggest H1 portfolio bets
Seeking Alpha · 3d ago
Weekly Report: what happened at GENB last week (0629-0703)?
Weekly Report · 3d ago
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 07/01 12:02
Why Constellation Brands Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 07/01 09:10
Generate Biomedicines releases corporate presentation on programmable biology platform and clinical-stage pipeline
PUBT · 06/29 15:47
Cathie Wood's weekly recap: boosts AI, crypto bets; cuts Roku, China exposure
Seeking Alpha · 06/29 11:05
Weekly Report: what happened at GENB last week (0622-0626)?
Weekly Report · 06/29 10:34
More
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Webull offers Generate Biomedicines Inc stock information, including NASDAQ: GENB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GENB stock methods without spending real money on the virtual paper trading platform.